A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects

62 participants · First posted May 18, 2022

Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer

52 participants · First posted Aug 14, 2026

A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)

270 participants · First posted Nov 26, 2021

CU-40101

CU-06

CU-01

CU CHEMIE UETIKON GmbH

Germany

CU Anschutz Medical Campus

United States

CHULALONGKORN UNIVERSITY

Thailand

Cutia Therapeutics Receives NMPA Approval for Topical Dutasteride Clinical Trial in Androgenetic Alopecia

Cutia Therapeutics' CU-40102 Demonstrates Efficacy in Phase III Trial for Androgenetic Alopecia

CU Cancer Center's Innovative Approaches Lead to Higher Survival Rates